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A B S T R A C T
Introduction. Vaginal dryness due to vaginal atrophy is a common complaint of postmenopausal women, interfering
with sexual function and quality of life. Hormone replacement therapy is the only effective therapy but with known
risks that leave unmet medical needs. A new product, ZP-025 vaginal gel, containing puriﬁed (dialyzed lyophilized)
bovine colostrum, has been developed for the treatment of vaginal dryness secondary to vaginal atrophy.
Aim. The study aims to investigate the effects of intravaginal application of ZP-025 on vaginal atrophy using an
animal model.
Methods. Ovariectomized female Sprague-Dawley rats were used. Three weeks after surgery, rats were divided into
four groups and treated for 4 weeks (twice a day) with placebo or ZP-025 at low (0.5%) or high (2.3%) concentrations
of colostrum; in the control group, rats did not receive any treatment. Changes in vaginal blood ﬂow due to pelvic
nerve stimulation were assessed by laser Doppler ﬂowmetry and vaginal tissue was collected for histological assay.
Main Outcome Measures. The main outcome measures were vaginal blood ﬂow before and after pelvic nerve
stimulation and histology of vaginal epithelium.
Results. Treatment with ZP-025 to ovariectomized rats induced an increase of vaginal blood ﬂowparameters (vascular
capacitance, amplitude and area under the curve of the response) in response to pelvic nerve stimulation comparedwith
control group, statistically signiﬁcant at 2.3%. Vaginal epithelium showed a physiological estrous cycle aspect in
treated animals, with at least ﬁve cell layers vs. one or two cell layers in control rats. As expected from a topical
formulation, systemic effects on body weights and uterine wet weights were not observed with application of ZP-025.
Conclusions. In this study, the new product ZP-025, containing puriﬁed colostrum, was shown to have beneﬁcial
effects on vaginal atrophy in ovariectomized rats, improving vaginal hemodynamics and thickness of vaginal
epithelium. Vailati S, Melloni E, Riscassi E, Behr Roussel D, and Sardina M. Evaluation of the effects of a new
intravaginal gel, containing purified bovine colostrum, on vaginal blood flow and vaginal atrophy in
ovariectomized rat. Sex Med 2013;1:35–43.
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Introduction
Vaginal atrophy is caused by a decrease inoestrogen production and is a common
complaint of postmenopausal women, interfering
with sexual function and quality of life. In about
45% of menopausal women, vaginal atrophy can
be clinically manifest as a syndrome of vaginal
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dryness, itching, irritation, and dyspareunia
[1,2].
The vaginal atrophy becomes clinically appar-
ent 4–5 years after menopause and its hallmarks
are thinning of vaginal epithelia layers, increased
vaginal pH, decrease in the local blood ﬂow, and
diminished vaginal secretion. Clinical studies have
shown that these signs signiﬁcantly correlate with
the decline in circulating ovarian hormones [3–6].
While systemic and local estrogen-based hor-
monal therapy is effective in treating symptoms of
vaginal atrophy in postmenopausal women [3,7–
9], these medications are contraindicated in some
populations (women with unknown vaginal/
uterine bleeding or those with a known or sus-
pected ovary, endometrial cancer, and breast
cancer) and other women choose not to take them
for fear about their safety [10,11]. Because of these
issues, recent work has focused on developing
more speciﬁc, and in many cases nonhormonal,
alternatives to traditional postmenopausal hor-
monal therapy to treat vaginal dryness in presence
or in absence of vaginal atrophy [12].
Zambon SpA (Bresso, Milan, Italy) has devel-
oped a gel product (ZP-025 vaginal gel—
Monurelle Biogel), containing puriﬁed bovine
colostrum to be administrated topically, for the
treatment of vaginal dryness also in presence of
vaginal atrophy. Colostrum is a substance pro-
duced from female mammary gland during the
ﬁrst few hours postpartum, and numerous investi-
gators have reported that the colostrum imparts
many advantages for the development of the
infants [13]. Thanks to its constituents, colostrum
is able to help the local defense (immunoglobulin
A); modulate the immunitary response (immuno-
globulin E, M, G); promote antibacteric and
antiviral action (lactoferrin and transferring);
modulate the inﬂammation factors (cytokine,
interleukine); promote normal cell growth, normal
cell activities, cell migration and proliferation, and
tissue repair (transforming growth factor alpha
and beta; epidermal growth factor); stimulate the
mucosal restore; and accelerate wound healing
(insulin-like growth factors—IGF-1 and -2). In
particular, IGF-1 is involved in the regulatory
feedback of growth hormone [14] and interferes
with insulin-like growth factor binding proteins
[15]. To date, based on the best scientiﬁc knowl-
edge available to us, no sexual hormones are
directly present in bovine colostrum.
Because vaginal mucosa, because of its anatomic
and physiologic features, is exposed to epithelium
damage and to vaginal ecosystem and local defense
factors alterations, colostrum can help in promot-
ing the mucosal trophic restoration and preserving
from bacteric and viral aggression. Our hypothesis
is that topical application of colostrum could have
a beneﬁcial effect speciﬁcally on vaginal atrophy.
Besides puriﬁed colostrum, this vaginal gel con-
tains other natural substances with humectants,
hydrating, re-epithelizing, and antioxidant pro-
perties at concentrations <5%: betaine, sericin,
panthenol, glycerin, tocopherol, Lepidium meyenii
root extract.
The aim of the present study was to assess the
effect of ZP-025 vaginal gel on vaginal blood ﬂow
and tissue morphology using ovariectomized
(OVX) rats as an animal model for vaginal atrophy.
This well-characterized experimental model is very
useful to induce experimentalmenopause, as within
a short period of time postovariectomy, female rats
without ovarian hormone secretion mimic many
human postmenopausal changes, including vaginal
atrophy. It has been well documented also in this
animal model that estrogen replacement increases
pelvic blood ﬂow and restores the structural and
functional integrity of vaginal tissue [16–21], con-
ﬁrming that the loss of estrogens is the key factor
leading to vaginal atrophy.
Materials and Methods
Animals and Treatments
Adult nonpregnant female Sprague-Dawley rats
(Elevage Janvier, Le Genest-St-Isle, France, 8–10
weeks old, 200–225 g) were housed 7 days prior to
the beginning of the experiments, with free access
to standard chow and water and maintained on an
inversed 12-hour dark/light cycle (10:00/22:00).
All procedures were performed in accordance with
the legislation on the use of laboratory animals
(NIH publication N°85-23, revised 1996) and
Animal Care Regulations in force in France as of
1988 (authorization from competent French Min-
istry of Agriculture—Agreement No. A91-471-
109, May 2009).
After a 1-week acclimation period, all rats
were bilaterally ovariectomized under 1–1.2%
isoﬂurane anaesthesia (CSP, Cournon, France).
After 3 weeks of postsurgical period to induce
artiﬁcial menopause, the rats were divided into
four groups (n = 8/group) and received 50 μL of
the following intravaginal treatments, delivered
via a micropipette twice a day (8–10 hours inter-
vals) for 4 weeks: in the control group, rats did not
receive any treatment but a micropipette tip was
introduced into the vagina; in the placebo group,
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rats received ZP-025 gel without colostrum; in the
treated groups, rats received ZP-025 gel contain-
ing 0.5% or 2.3% of bovine colostrum.
Body weight was recorded twice a week.
In Vivo Assessment of Vaginal Blood Flow
At the end of the treatment period, changes in
vaginal blood ﬂow in response to pelvic nerve
stimulation were assessed in each rat of the four
experimental groups. Vaginal engorgement was
measured by monitoring blood ﬂow in the vaginal
wall using laser Doppler perfusion measurement
(LDPM) (Oxford Optronix Ltd, Abingdon,
Oxfordshire, UK) in baseline conditions and after
pelvic nerve stimulation. LDPM is expressed in
arbitrary units (au).
Before measurements, rats were anesthetized
with urethane 1.2 mg/kg and their temperature
was maintained at 37°C (rectal temperature
37 ± 0.3°C) using a homeothermic blanket. Then
rats were tracheotomized to prevent aspiration of
saliva and, when required, to perform artiﬁcial
ventilation. The carotid artery was catheterized
with polyethylene tubing ﬁlled with heparinized
saline (25 UI/mL) to record blood pressure (BP)
via a pressure transducer (Elcomatic 750, Glasgow,
UK).
The pelvic nerve (PN) was exposed via a
suprapubic midline incision and separated from
connective tissue using a dissecting microscope.
PN was placed on bipolar platinum stimulating
electrode connected to an electrical stimulator
(A-M Systems, Model 2100, Phymep, France)
delivering a series of square-wave pulses. The non-
invasive laser Doppler microprobes were placed
against the inner lateroventral side of the vaginal
lumen 15–17 mm distal from the vulva.
Simultaneous computerized measures of BP
and LDPM were performed at different time-
points: at t = 0, the continuous recording of BP
and LDPM started and the laser probe was placed
on the vagina wall to perform baseline measure-
ments of vaginal wall perfusion; at t = 30 minutes,
the laser probe was positioned and the LDPM
stabilized for 10 minutes, until the PN stimulation;
at t = 40 minutes and at 5-minute intervals there-
after, the PN was stimulated at square-waves
pulses of 1 ms, 6 V, for 30 seconds by different
stimulation frequencies (2, 4, 6, 8, and 10 Hz:
these different electrical stimulations were ran-
domized and repeated twice in view of establishing
a frequency–response curve for each animal); at
t = 90 minutes, the recording ended.
The following parameters were studied: baseline
LDPM and BP, measured during the 30-minute
baseline period before any PN stimulation (mean
of three measurements made on three different
regions of vaginal wall for 10 minutes period each).
And, for each PN stimulation:
• The mean maximal amplitude of the response,
being the percentage of LDPM increase calcu-
lated as follows: ΔLDPM × 100/Base LDPM,
and expressed in %
• The area under the curve (AUC) of the response
calculated for the entire response, normalized
by Base LDPM and expressed in % × second
• The vascular capacitance, which corresponds
to the ratio of the mean maximal amplitude
of the response to the corresponding mean BP
expressed in %/mm Hg
Parameters of LDPM responses were normalized
to their own baseline LDPM measurement (Base
LDPM, representing 100%) in order to reliably
compare each rat, as blood ﬂow through any given
tissue is dependent upon the systemic BP.
Tissue Harvesting and Processing
At the end of LDPM experiments, all the rats were
euthanized with an overdose of urethane and the
vagina and the uterus (including uterine horns and
cervix) were harvested.
The tissues were immediately placed in cold
physiological saline to eliminate excess of blood and
carefully dissected free from surrounding tissue.
The vagina and the uterus were weighed (wet
weight) and then ﬁxed for 48 hours in 10% neutral
buffered formalin and stored in 70% ethanol at
4°C. After dehydration and embedding in parafﬁn
wax, sections of the tissues were cut at 5 μm thick-
ness and stained with hematoxylin and eosin for
unblinded histological analysis.
The entire vagina was evaluated considering
three portions:
1. The proximal part, near the cervix
2. The distal part, near the vulva
3. The central part, the portion between proximal
and distal part
Data Analysis
All results were expressed as mean ± SEM. Grubbs
test was used for the detection and exclusion of
outliers. Comparison between treatment groups
were analyzed by Student’s t-test or a one-way
analysis of variance (anova) or a two-way anova.
P values < 0.05 were considered signiﬁcant.
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Results
BodyWeight
In all groups, rat body weights regularly increased
from the day of ovariectomy until the beginning of
the treatment period (day 21) (Figure 1A). There
was no signiﬁcant difference between experimen-
tal groups in the body weights measured at the
time of surgery (day 0—one-way anova P > 0.05)
nor at the time of starting treatments (day 21).
Likewise, twice-a-day treatments with placebo,
ZP-025 0.5%, and ZP-025 2.3% for 4 weeks did
not modify the body weight change between the
beginning (day 21) and the end of applica-
tion period (day 49) (Figure 1B) compared with
control.
Determination of Peripheral Sexual Response:
Vaginal Blood Engorgement by LDPM
The intravaginal application of placebo for 4
weeks, 3 weeks after ovariectomy, did not signiﬁ-
cantly change baseline mean BP and baseline
LDPM compared with control group (Figure 2).
Likewise, neither ZP-025 0.5% nor ZP-025 2.3%
modiﬁed either BP (Figure 2A) or baseline LDPM
(Figure 2B) compared with placebo.
Following PN stimulation, the parameters of
vaginal blood engorgement (i.e., maximal ampli-
tude of the response, AUC of the response, and
vascular capacitance) increased in each group in
parallel with the frequency of PN electrical stimu-
lation. No statistically signiﬁcant difference was
shown in each parameter between placebo and
control group (Figure 3). The efﬁcacy of the
product was evaluated by statistical comparison
between the two different doses of colostrum and
placebo in order to establish a possible superiority
of the product due to the presence of colostrum.
After 4 weeks of intravaginal twice-daily treatment
with ZP-025 0.5%, no statistical difference in the
amplitude, the AUC, and the vascular capacitance
was present when compared with placebo group
(Figure 4). On the contrary, the treatment with
ZP-025 2.3% signiﬁcantly increased all the param-
eters of vaginal blood engorgement following PN
stimulation, that is, maximal amplitude of the
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Figure 1 Evolution of (A) body
weight starting from surgery until the
end of the treatment and (B) body
weight change during the 4 weeks
of intravaginal treatment in either
placebo or ZP-025 0.5% or ZP-025
2.3% groups compared with control
group in ovariectomized rats (one-
way ANOVA, nonsignificant).
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response, AUC of the response, and vascular
capacitance when compared with placebo group
(***P < 0.001 for each parameter, two-way anova
analysis) (Figure 4).
Vagina and UterusWeights
Intravaginal treatment with placebo, ZP-025
0.5%, or ZP-025 2.3% for 4 weeks in OVX rats
did not induce any modiﬁcation of the vagina and
uterus macroscopic aspect. Indeed, in all groups of
treatment (control, placebo, ZP-025 0.5%, and
ZP-025 2.3%), the appearance of vagina and
uterus was normal and thin uterine horns were
observed.
Moreover, after 4 weeks of twice daily
intravaginal treatment with placebo, ZP-025 0.5%
and ZP-025 2.3%, vagina and uterus tissue wet
weight normalized to body weight were not
modiﬁed when compared with control (Table 1).
Histopathological Evaluation of Vagina and Uterus
Seven weeks after ovariectomy, at the end of the
treatment period, uterus and cervix atrophy
was noted in all animals of all experimental
groups. The atrophy involved endometrium and
myometrium.
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Figure 3 Effect of twice-a-day intra-
vaginal treatment with placebo or
control in anesthetized ovariecto-
mized rats on vaginal blood engorge-
ment: amplitude of the response (A);
AUC of the response (B); and vascu-
lar capacitance (C) elicited by pelvic
nerve electrical stimulations at in-
creasing frequencies (two-way ANOVA
analysis). AUC = area under the
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Atrophy was also noted in vaginal epithelium in
all control animals (Figure 5A). In particular, a sig-
niﬁcant thinning was present in the proximal and
central part of the vagina epithelium, which was
reduced to one or two cell layers and reaching at
maximum three to four cell layers in the distal part
of some control animals.
On the contrary, the vaginal epithelium showed
a physiological estrous cycle morphological aspect
in animals receiving placebo or ZP-025 0.5% or
ZP-025 2.3% (Figure 5B). The epithelium con-
sisted of one to two cell layers with ﬂattened
superﬁcial cells only in the proximal part with pro-
gressive increase in cell layers (at least 5) in the
central and distal part. In the central portion, the
superﬁcial layers of epithelial cells were in some
instances cuboidal with minimal muciﬁcation,
while in the distal portion, the epithelium of at
least ﬁve cell layers was squamous with presence of
stratum corneum in the majority of animals receiv-
ing placebo or ZP-025 0.5% or ZP-025 2.3%.
Such changes are characteristic of estrous cycle
[22].
Discussion
Our study shows that the application of a new
vaginal gel containing puriﬁed colostrum for 4
weeks provided beneﬁcial effects in an animal
model of vaginal atrophy.
Frequency-depending increases of vaginal
blood ﬂow elicited by PN stimulation is a widely
used experimental paradigm to mimic female
sexual response in intact animals [16,23–25].
Ovariectomy, reducing estrogen levels, causes a
marked decrease in vaginal hemodynamics, also in
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Figure 4 Effect of twice-a-day intra-
vaginal treatment with placebo or
ZP-025 0.5% or ZP-025 2.3% during
4 weeks in anesthetized ovari-
ectomized rats on vaginal blood
engorgement: amplitude of the
response (A); AUC of the response
(B); and vascular capacitance (C)
elicited by pelvic nerve electrical
stimulations at increasing frequen-
cies. (*P < 0.05, ***P < 0.001, 2-way
ANOVA). AUC = area under the curve;
ns = nonsignificant.
Table 1 Vagina and uterus wet tissue–body weight ratios at the end of the 4-week treatment in OVX rats
Wet weight–body weight ratio (g/100 g) (mean ± SEM)
Control Placebo ZP-025 0.5% ZP-025 2.3%
Vagina 0.030 ± 0.001 0.032 ± 0.002 0.032 ± 0.001 0.034 ± 0.01
Uterus 0.027 ± 0.001 0.026 ± 0.001 0.029 ± 0.001 0.029 ± 0.001
ns = nonsignificant, one-way ANOVA
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response to PN stimulation [16]; however, estro-
gen replacement in OVX rats ameliorates vaginal
blood ﬂow and relating parameters, following PN
stimulation [16].
In this study, after PN stimulation at different
frequencies, only the treatment with ZP-025 con-
taining 2.3% of colostrum increases all the param-
eters of vaginal blood engorgement, that is,
maximal amplitude of the response, AUC of the
response, and vascular capacitance in a statistically
signiﬁcant manner. On the contrary, for the same
parameters no differences between control and
placebo were noted and only a trend with the low
dose of colostrum was present when compared
with placebo.
Previous studies demonstrate that ovariectomy
produces a signiﬁcant decrease in animal uterus
and vaginal tissue wet weight and epithelial thick-
ness [16,19,26]. In fact, the stratiﬁed squamous
epithelium, consisting of approximately six to
eight layers of cells in intact rats, is reduced to one
or two cell layers after ovariectomy. Estrogens,
when delivered subcutaneously, restore the uterus
and vaginal wet weight as well as epithelial thick-
ness, with the same number of layers seen in the
non-OVX rats [16,26].
Our study shows that a twice-a-day application
of placebo, ZP-025 at 0.5% and 2.3% of colostrum
to OVX rats for 4 weeks increases the thickness of
vaginal epithelium compared with untreated OVX
rats and a physiological estrous cycle morphologi-
cal aspect of the vaginal epithelium is observed.
Despite the fact that the product is not able to
restore completely the epithelial thickness to the
same condition as before the ovariectomy or with
estrogens [26], nor it is able to signiﬁcantly
enhance tissue wet weight, an evident effect is
present in treated animals, with an epithelium of at
least ﬁve cell layers, compared with one or two cell
layers in untreated animals. This effect of ZP-025
at all concentrations of colostrum could be due not
only to the well-known growth factors included
in the colostrum per se, but also to the other
re-epithelizing components present in the
formula, such as betaine, sericin, and panthenol
[27,28]. Moreover, the antioxidant compound
(Vitamin E) included in the product could retard
biologically destructive chemical reactions in
living organisms through their ability to scavenge
oxidants and free radicals [29]. As a consequence,
the placebo cannot be considered totally devoid of
any effect, as shown in the histology analysis of
vaginal epithelium, where the response to placebo
indicates that it is not completely inert; however, a
more complete response was obtained with the gel
containing colostrum on other parameters.
Finally, the fact that uterus atrophy remains his-
tologically unchanged in all experimental groups
after a 4-week treatment indicates that the effects
of the product are speciﬁcally limited to the
vagina, as expected for a topical preparation. This
is in contrast with estrogen preparations for
topical use, that anyway lead to increased systemic
estrogen levels, thus increasing the well-known
risk of systemic actions [30–32].
Although many women report that they gained
weight at or near the time of their menopause
[33], the amplitude and even the reality of the
menopause-related gain in weight is not consistent
between studies [34,35].
In rats, ovariectomy is associated to body
weight increase [23,36], mainly due to hyper-
phagia and hypoactivity [37,38]. It has been shown
that 17β-estradiol hormonal replacement is able to
reduce body weight gain in OVX rats [36,38],
while in the present study with ZP-025 there
is no signiﬁcant difference between experimental
Epithelium (at least 5 cell 
layers with stratum 
corneum) in the central 
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Estrous.
Epithelium (1-2 cell 
layers) in the proximal 
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Figure 5 Hematoxylin and eosin staining of rat vaginal epi-
thelium at ×100 magnification. Representative tissue sec-
tions are shown. (A) Vaginal epithelium of a rat from control
group; (B) vaginal epithelium of a rat receiving twice-a-day
intravaginal application of ZP-025 2.3% for 4 weeks. Tissue
from control animal shows an atrophic vaginal epithelium,
with a lower number of cell layers (A). The treatment with
ZP-025 2.3% is able to restore an estrous condition in
ovariectomized rat (B).
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groups in the animal body weight, both measured
at the start of treatments and at the end (after 4
weeks of treatment).
Conclusion
The new ZP-025 vaginal gel containing colostrum
improves vaginal hemodynamics and thickness
of vaginal epithelium in rats with OVX-induced
vaginal atrophy. The marked changes in the
vaginal hemodynamics and histology resulting
from estrogen deprivation are improved by a treat-
ment with ZP-025 containing 2.3% concentration
of puriﬁed colostrum. Clinical trials are necessary
to determine if these beneﬁts could be translated
to menopausal women.
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